We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Assay Identifies Which Species Patients with Fish Allergy Can Tolerate

By LabMedica International staff writers
Posted on 20 Sep 2022
Print article
Image: ALEX2 is a state-of-the-art multiplex ELISA test based on proven immunoassay chemistry and detection methods (Photo courtesy of Macro Array Diagnostics)
Image: ALEX2 is a state-of-the-art multiplex ELISA test based on proven immunoassay chemistry and detection methods (Photo courtesy of Macro Array Diagnostics)

Fish allergy is an immune hypersensitivity to proteins found in fish. Symptoms can be either rapid or gradual in onset. The latter can take hours to days to appear. The former may include anaphylaxis, a potentially life-threatening condition which requires treatment with epinephrine.

Diagnostic tests for fish allergy included skin-prick tests and blood antibody tests, which are used to check for the presence of an immune protein called an anti-parvalbumin antibody, which the body produces in response to a fish allergen. If the tests aren’t conclusive, an allergist may recommend an oral food challenge.

Allergy Specialists at the University Hospital St. Pölten (St. Pölten, Austria) and their colleagues investigated whether multiplex immunoglobulin E (IgE) testing reveals potentially tolerated fish through absence of IgE to parvalbumin (PV) and extracts from specific species. Sera from a cohort that comprised 263 patients (median age, 12 years; range, 1-65; 160 of whom were males) from Austria, China, Denmark, Luxembourg, Norway and Spain with a documented clinical history of fish allergy and confirmed sensitization to fish.

The team used a research version of the ALEX2 multiplex IgE quantification assay (Macro Array Diagnostics, Vienna, Austria). Specific IgE to PVs from 10 fish species (nine bony and one cartilaginous), and to extracts from seven species was quantified. The IgE signatures of individual patients and patient groups were analyzed using SPSS and R.

The scientists reported that up to 38% of the patients were negative to cod PV, the most commonly used molecule in fish allergy diagnosis. Forty-five patients (17%) tested negative to PVs, but positive to the respective fish extracts, underlining the requirement for extracts for accurate diagnosis. Between 60% (Spain) and 90% (Luxembourg) of the patients were negative to PV and extracts from ray, a cartilaginous fish, indicating its potential tolerance. Up to 21% of the patients were negative to at least one bony fish species. Of the species analyzed, negativity to mackerel emerged as the best predictive marker of negativity to additional bony fish, such as herring and swordfish.

The team also calculated the probability that all three IgE tests would be negative for a species if tolerance to other species is known. They found patients who are negative for tuna are 92% likely to be negative for ray and swordfish. Patients who are negative for mackerel are 93% likely to be negative for herring and ray and 86% likely to be negative for swordfish.

Tanja Kalic, PhD, and Heimo Breiteneder, PhD, a professor of pathophysiology, both study authors, said, “The most commonly used fish allergen in diagnosis is cod parvalbumin, Gad m 1. In the study up to 38% of fish-allergic patients, depending on country of origin, were negative to this molecule, clearly showing that additional parvalbumins from other fish species are required in order to avoid false-negative testing of patients.”

The authors concluded that parvalbumins and extracts from multiple fish species relevant for consumption should be used in fish-allergy diagnosis, which may help identify potentially tolerated species for individual patients. The study was published on August 21, 2022 in The Journal of Allergy and Clinical Immunology: In Practice.

Related Links:
University Hospital St. Pölten
Macro Array Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.